Avinger Inc. (NASDAQ:AVGR) fell 1.7% during mid-day trading on Wednesday . The company traded as low as $6.23 and last traded at $6.26, with a volume of 104,097 shares trading hands. The stock had previously closed at $6.37.

A number of research firms have issued reports on AVGR. Zacks Investment Research upgraded Avinger from a “sell” rating to a “hold” rating in a research note on Thursday, May 19th. BTIG Research reiterated a “buy” rating and issued a $18.00 target price on shares of Avinger in a research note on Friday, July 15th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $20.00 target price on shares of Avinger in a research note on Wednesday, March 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $18.75.

The company’s 50-day moving average price is $10.39 and its 200 day moving average price is $12.48. The firm’s market cap is $78.32 million.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings data on Wednesday, May 4th. The medical device company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.11. On average, equities research analysts predict that Avinger Inc. will post ($4.26) EPS for the current fiscal year.

In other news, Director Donald A. Lucas sold 9,309 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $12.58, for a total value of $117,107.22. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Himanshu Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $13.40, for a total value of $134,000.00. Following the completion of the transaction, the insider now owns 87,220 shares in the company, valued at approximately $1,168,748. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Avinger stock. Paradigm Capital Management Inc. NY raised its position in Avinger Inc. (NASDAQ:AVGR) by 41.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 367,056 shares of the medical device company’s stock after buying an additional 108,222 shares during the period. Paradigm Capital Management Inc. NY owned about 2.91% of Avinger worth $8,336,000 as of its most recent filing with the SEC.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.